Autologous PBSC transplantation is a preferred treatment for patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS syndrome). However, data on stem cell mobilization in POEMS syndrome are limited. We retrospectively reviewed outcomes and factors prognostic of mobilization in newly diagnosed patients with POEMS syndrome. A total of 56 patients (41 men and 15 women) were included and the median age was 45 years (range, 24-62). All patients underwent mobilization with CY plus granulocyte CSF (G-CSF) (n ¼ 38) or G-CSF alone (n ¼ 18). The median total number of harvested CD34 þ cells was 2.01 Â 10 6 /kg (range, 0.18-9.0 Â 10 6 /kg). In all, 29 (51.8%) patients failed to yield more than 2 Â 10 6 /kg CD34 þ cells, and among them, 7 (12.5%) patients yielded o1 Â 10 6 /kg CD34 þ cells. The overall mobilization-related morbidity was 23.3% and acute renal failure was the most common complication during mobilization. Multivariate analysis showed that hepatomegaly (odds ratio 0.06, 95% confidence interval (CI) 0.01-0.43) and mobilization regimen of G-CSF alone (odds ratio 0.08, 95% CI 0.01-0.70) were independent prognostic factors for successful mobilization in POEMS syndrome. In conclusion, mobilization in newly diagnosed patients with POEMS syndrome is challenging with low yield of CD34 þ cells and high morbidity. Induction therapy before mobilization might improve the efficacy and safety of mobilization.
INTRODUCTION
POEMS syndrome, also called Crow-Fukase syndrome, is a rare plasma cell dyscrasia characterized by polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes. Additional features include papilledema, extra-vascular volume overload, sclerotic bone lesions and Castleman's disease. 1, 2 The pathogenesis of POEMS syndrome is not fully understood, but there is increasing evidence suggesting that high levels of serum vascular endothelial growth factor (VEGF) may contribute to certain features of POEMS syndrome such as extra-vascular volume overload, organomegaly and hemangioma. The course of POEMS syndrome is chronic and the median survival is usually 45 years. The main causes of death are cardiopulmonary failure, renal failure and infection. 1, 2 There is no standard treatment for POEMS syndrome. In the past decade, melphalan-based therapy has made significant progress in the treatment of POEMS syndrome, including chemotherapy of melphalan and dexamethasone, 3 and highdose melphalan followed by autologous PBSC transplantation. [4] [5] [6] Several studies have reported that autologous transplantation could achieve excellent clinical responses in patients with POEMS syndrome. However, this therapy was associated with high mortality of about 8%. [4] [5] [6] [7] So far, few studies have reviewed the outcome and efficiency of PBSC mobilization in patients with POEMS syndrome. 8 There are limited data on the incidence of complications associated with mobilization, prognostic factors for successful mobilization and outcomes of subsequent transplantation. We retrospectively reviewed outcomes and prognostic factors of PBSC mobilization in newly diagnosed patients with POEMS syndrome from a single institute with two specific aims: (1) to explore the associations between successful mobilization and treatment regimen and various clinical factors and (2) to report incidence of complications associated with mobilization.
MATERIALS AND METHODS Patients
We retrospectively reviewed clinical data of all 56 patients with newly diagnosed POEMS syndrome who underwent PBSC mobilization at Peking Union Medical College Hospital between January 2007 and December 2011. These patients were referred to our hospital from more than 30 centers nationwide. They met the diagnostic criterion proposed by Dispenzieri. 9 In brief, this diagnostic criterion consists of two major criteria (polyneuropathy and monoclonal plasma proliferative disorder) and seven minor criteria (bone lesion, Castleman's disease, organomegaly, edema, endocrinopathy, skin changes and papilledema). Two major criteria and at least one minor criterion were required for a diagnosis. The Institutional Review Board of Peking Union Medical College Hospital approved this study.
Detailed clinical information at the time of mobilization was extracted from patients' records for the current study. Overall neuropathy limitation scale with normal value zero in each limb was used to assess neurological disability as described elsewhere. 10 Patients with total overall neuropathy limitation scale score 43 were considered as having severe neuropathy. Signs of edema, ascites, lymphadenopathy, splenomegaly and hepatomegaly were qualitatively evaluated by physical examination, ultrasound and/or computed tomography scanning. A complete bone survey including X-rays of skull, spine, pelvis, femur and humerus was conducted to detect bone lesions in all patients. Echocardiogram was used to examine systolic pulmonary arterial pressure in all patients. Patients with systolic pulmonary arterial pressure 450 mm Hg were considered as having pulmonary hypertension. All patients further received pulmonary function tests at the time of mobilization. Serum VEGF levels (normal value was o500 pg/mL) were measured by ELISA assay as previously described.
11
Mobilization of PBSC The original mobilization regimen was designed as CY plus granulocyte CSF (G-CSF) (C þ G). Two patients developed neutropenia with fever and one patient had respiratory failure due to bacterial pneumonia among the first six patients who received C þ G. Then mobilization regimen was changed to G-CSF alone. However, when the lower yield of CD34 cells was observed from 18 patients mobilized by G-CSF alone, the mobilization regimen was changed back to C þ G for the next 32 patients. Therefore, 38 patients underwent mobilization with CY (2 g/m 2
) and G-CSF (5-10 mg/kg/ day) s.c., beginning on day 8 following the initiation of chemotherapy until completion of apheresis. Collection started on day 11 or 12 after chemotherapy. Eighteen patients had received mobilization with G-CSF (5-10 mg/kg/day) alone for 4 days, and then stem cells were collected. All patients underwent leukapheresis using the Haemonetics MCS þ cell separator (Haemonetics Corporation, Braintree, MA, USA). The estimated blood volume was processed three times during each collection. Citrate dextrose solution was used as an anticoagulant. Total nucleated cell count and CD34 þ cell concentration was measured immediately after completion of apheresis. Patients were defined as poor mobilizers if they did not obtain a minimum threshold of 2 Â 10 6 /kg CD34 þ cells within a single mobilization attempt or they failed to undergo collection. Otherwise, patients were defined as good mobilizers. In addition, patients with the number of mobilized CD34 þ cells o1 Â 10 6 /kg were considered as very poor mobilizers. All patients received only one mobilization attempt.
Statistical methods
A total of 17 explanatory variables were measured in the analysis, including gender, age, severe neuropathy, M-protein type, lymphadenopathy, hepatomegaly, splenomegaly, hypothyroidism, diabetes, papilledema, edema, ascites, pulmonary hypertension, pulmonary function tests abnormalities, high serum VEGF level, and mobilization regimen. The primary outcome variable was status of mobilization (good vs poor), as described in the previous sub-section. For each explanatory variable, a bivariate analysis was performed to examine its association with the outcome, using Chi-square test, as all explanatory variables were categorically coded. Only those explanatory variables with significant bivariate association were entered into a multivariate logistic regression to test their independent associations with the outcome. In addition, the outcome of mobilization was also measured by the number of CD34 þ cells a patient yielded after the therapy. This variable was coded as continuous and only bivariate (unadjusted) association with the treatment regimen was tested, using Mann-Whitney U-test. The secondary outcome variable was incidence of complications, stratified by type of complication. Only bivariate Chi-square test was performed to assess the unadjusted association between treatment therapy and complication. SPSS 17.0 software (SPSS Inc, Chicago, IL, USA) was used for all analyses.
RESULTS

General characteristics of patients
A total of 56 newly diagnosed patients (41 men and 15 women) were included in this study. The median age was 45 years (range, 24-62 years). In all, 50 patients (89.3%) had all five typical clinical features of 'POEMS'. All patients had motor-sensor neuropathy and the median total overall neuropathy limitation scale score was 4 (range, 0-10). All patients had detectable M protein by serum immunofixation electrophoresis. The type of M protein was restricted to l light chain including IgAl (60.7%), IgGl (35.7%) and l alone (3.6%). Castleman's disease was diagnosed in 11 out of 17 patients who underwent lymph node biopsy. The median serum VEGF level was 3422 pg/mL (range, 111-13 867 pg/mL). In all, 13 (23.2%) patients had renal failure with creatinine clearance rate o60 mL/min, in which 2 patients had creatinine clearance rate o30 mL/min. In addition, the extra-vascular volume overload including edema and ascites, papilledema, thrombocytosis, bone lesions and pulmonary arterial hypertension were also common in these patients. The median time from onset to diagnosis was 13 months (range, 1-80 months). Table 1 outlines the general characteristics of the 56 patients.
Outcomes of mobilization Two different mobilization regimens were used as described in the methods. In all, 38 (67.9%) patients received C þ G therapy, whereas 18 (32.1%) patients received G-CSF alone (G). Of 56 patients, 54 completed mobilization and collection of stem cells, whereas the remaining two patients failed to undergo collection of stem cells. One patient in the G group suffered from recurrent ventricular tachycardia after administration of G-CSF and the other /kg (range, 0.18-9.0) in these 54 patients. The median number of apheresis was 2 (range, 1-4). A total of 29 (51.8%) patients were identified as poor mobilizers including those who failed to yield 42 Â 10 6 /kg CD34 þ cells (n ¼ 27) and those who failed to undergo collection (n ¼ 2). The other 27 (48.2%) patients were regarded as good mobilizers. The median total yield of CD34 þ cells was 1.38 Â 10 6 (range, 0.18-1.92) and 2.76 Â 10 6 /kg (range, 2.1-9.0) in poor and good mobilizers, respectively. In addition, o1 Â 10 6 /kg CD34 þ cells were collected from five patients and the median number was 0.57 Â 10 6 /kg (range, 0.18-0.87). In all, 42 out of 56 (75%) 6 /kg (range, 1.1-1.9) in good and poor mobilizers, respectively. However, the median times to neutrophil (neutrophil count was X0.5 Â 10 9 /L) and platelet engraftment (platelet count was X20 Â 109/L unsupported by platelet transfusion) were similar in these two groups (12 (range, 10-21) vs 13 (range, 8-18) days, P ¼ 0.63 and 13 (range, 9-27) vs 15 (range, 9-22) days, P ¼ 0.68).
Mobilization-related toxicity
No mobilization-related death was observed. However, the incidence of mobilization-associated complications was high. Table 2 summarizes the mobilization-related complications in these 56 patients. Seven (12.5%) patients developed acute renal failure and one of them required short-term dialysis. In all, 3 out of 13 (23.1%) patients with baseline creatinine clearance rate o60 mL/min developed acute renal failure, and 4 out of 43 (9.3%) patients with normal renal function had this complication (P ¼ 0.18). The injured renal function could be reversed to normal or baseline level in five patients after short-term support therapy. Three (5.4%) patients suffered from neutropenia with fever including two cases of unknown reason and one case of pneumonia with respiratory failure. In addition, deteriorated extra-vascular volume overload alone was observed in 2 (3.6%) patients and 1 (1.8%) patient had ventricular tachycardia of unknown origin following the administration of G-CSF. Therefore, the overall mobilization-related morbidity was 23.3%. The overall morbidity was similar between G and C þ G group (27.8% vs 21.1%, P ¼ 0.73).
Prognostic factors for successful mobilization
We further analyzed prognostic factors associated with successful mobilization (collection of X2.0 Â 10 6 /kg CD34 þ cells) (see Tables 3 and 4) . We observed that only 26.9% patients with hepatomegaly were mobilized successfully, compared with 66.7% in patients without hepatomegaly (P ¼ 0.003). The trend towards poorer mobilization in patients with hepatomegaly was documented also in multivariate analysis (odds ratio 0.06, 95% CI 0.01-0.43, P ¼ 0.005). The median number of total CD34 þ cells was higher in C þ G group than that in G group (2.38 Â 10 6 (range, 0.18-9.0) vs 1.64 Â 10 6 /kg (range, 0.42-3.17), P ¼ 0.04). In all, 60.5% patients mobilized by C þ G can get sufficient numbers of stem cells, compared with 422.2% patients in the G-CSF group (P ¼ 0.007). We also found that there were 4 (10.5%) and 3 (16.7%) patients who were unable to undergo sequential transplant due to collection failure or very poor mobilization in G þ C group and the G group, respectively. Multivariate logistic regression analysis confirmed that compared with C þ G, mobilization with G-CSF alone was less likely to induce successful mobilization (odds ratio 0.08, 95% CI 0.01-0.70, P ¼ 0.02). The proportion of successful mobilization was significantly lower in patients with ascites than that in the remaining patients without ascites (33.3% vs 62.1%, P ¼ 0.032). Renal failure was also identified as a prognostic factor for successful mobilization (23.1% vs 55.8%, P ¼ 0.038). However, the effect of both ascites and renal failure was not significant in the multivariate the model. Moreover, patients in the C þ G and the G group had similar hepatomegaly (44.7% vs 50%, P ¼ 0.712), ascites (44.7% vs 55.6%, P ¼ 0.449) and renal failure (18.4% vs 33.3%, P ¼ 0.217).
In the contrast, gender, age (X50 years), severe neuropathy, lymphadenopathy, splenomegaly, M-protein type, hyperthyroidism, diabetes, edema, pulmonary hypertension, pulmonary function test abnormality and serum VEGF level had no significant effect on stem cell mobilization in patients with POEMS syndrome (see Table 3 ).
DISCUSSION
The current study retrospectively reviewed outcomes and prognostic factors of mobilization in patients with POEMS syndrome. To the best of our knowledge, it is the first large study on mobilization in patients with POEMS syndrome. These results were based on data from 56 newly diagnosed patients with POEMS syndrome. The complete clinical data, including typical features and pulmonary hypertension, renal function, bone lesion and serum VEGF level at the time of mobilization, were obtained from all of the patients. PBSC transplantation was chosen as the firstline treatment for these patients after diagnosis and they had never received any previous treatments before mobilization.
Although we used mobilization schedules to mobilize and collect stem cells similar to those reported in previous studies, our outcome of mobilization is not as satisfactory as described before. [4] [5] [6] [7] [8] In our study, a sufficient number of CD34 þ cells (X2 Â 10 6 /kg) could be obtained in only 48.2% patients and 7 (12.5%) patients even could not undergo sequent transplantation because of very poor mobilization (CD34 þ cells o1 Â 10 6 /kg). In addition, mobilization in patients with POEMS syndrome did not appear as safe as reported previously. In our study, 23.2% patients develop various complications during mobilization. Acute renal failure (12.5%) was the most common complication and one patient requires short-term dialysis. We speculate that the following factors might have contributed to the inconsistent findings. First, our patients were newly diagnosed and treatmentnaive, whereas most patients in previous series had been Abbreviation: C þ G ¼ CY and granulocyte CSF; G group ¼ granulocyte CSF.
PBSC mobilization in patients with POEMS syndrome J Li et al pretreated by glucocorticoid, alkylating agents or novel agents. Second, the median time from onset to diagnosis was 13 months. Our patients, therefore, might have more active disease than others. Third, 420% patients had mild renal failure before mobilization, which might contribute to high mobilizationrelated renal complications. Patients with baseline renal failure appeared more likely to develop acute renal failure than those with baseline normal renal function (23.1% vs 9.3%), although the difference did not reach statistical significance. Moreover, the dose of CY used in our study (2 g/m 2 ) was lower than that in other studies (3-5 g/m 2 ). Shimizu et al. 8 recently reported that splenomegaly might be a predictive factor for poor mobilization in a series of 19 patients with POEMS syndrome. However, the current study showed that hepatomegaly, ascites and renal failure were associated with a decreased number of mobilized CD34 þ cells and splenomegaly had no significant effect on mobilization. However, our results were not contradictory with Shimizu's results. The apparent discrepancy may be explained by the hypothesis that disease severity has an important role in mobilization, which may be indicated by various clinical 'markers'. The observed difference only suggested difference in the 'marking' ability of various clinical variables in indicating disease severity. The result might be dependent on the number of patients and variables used in the analysis. Therefore, it is suggested that relieving the disease activity with induction therapies, such as dexamethasone alone or combination of novel agents including lenalidomide, thalidomide and bortezomib, before mobilization would improve the efficacy and safety of mobilization in patients with POEMS syndrome.
We further found out that serum VEGF level had no significant effect on the efficiency of mobilization. Although a high level of serum or plasma VEGF is a specific marker in POEMS syndrome and several studies have revealed the correlation between serum VEGF levels and disease course, serum VEGF level is not a perfect marker to indicate the severity of disease activity in patients with POEMS syndrome because the absolute value of serum VEGF level is not associated with the severity of disease. 12, 13 Either administration of G-CSF alone or in combination with CY is the classical strategy for PBSC mobilization in various malignant diseases including acute myeloid leukemia, lymphoma and myeloma.
14 Randomized trials have revealed that the use of G-CSF alone can obtain adequate number of CD34 þ cells and similar time to neutrophil and platelet engraftment, compared with the use of combination of CY and G-CSF. 15 Others document that G-CSF alone is a useful and safe mobilization regimen for patients with POEMS syndrome.
4-8 Nonetheless, we observed that G-CSF alone was inferior to C þ G for successful mobilization in patients with POEMS syndrome. In all, 77.5% patients were unable to collect enough CD34 þ cells and 16.7% patients could not undergo sequential transplant because of collection failure or very poor mobilization in G group. We also observed higher incidences of unpredictable complications, including acute renal failure and aggravated edema, in G group, compared with those in C þ G group (22.3% vs 13.1%, P ¼ 0.45), although the difference was not statistically significant. It is well known that POEMS syndrome is PBSC mobilization in patients with POEMS syndrome J Li et al characterized by imbalance between pro-inflammatory cytokines and their antagonists. 2 The use of G-CSF might increase the release of pro-inflammatory cytokines and enhance this imbalance, which could worsen certain clinical symptoms closely associated with pro-inflammatory cytokines, for example, extravascular volume overload, similar to capillary leak syndrome induced by G-CSF. 16, 17 Studies have showed that CY is one of the drugs that can effectively decrease the pro-inflammatory cytokine network. It is reported that combination of CY and prednisone is an effective treatment regimen for patients with POEMS syndrome. 1 In addition, Jimenez-Zepeda et al. 18 reported that short-term induction therapy of CY and prednisone before transplantation could significantly decrease the incidence of engraftment syndrome and reduce transplant-related mortality. Therefore, pretreatment with high dose of CY might decrease the level of pro-inflammatory cytokines, relieve disease activity and reduce G-CSF-related adverse effects, which might improve the efficacy and safety of mobilization. It is suggested that combination of CY and G-CSF would be the preferred mobilization regimen for newly diagnosed patients with POEMS syndrome.
It is not clear if the number of infused CD34 þ cells would have effect on long-term outcomes of patients undergoing autologous transplantation. Although there was no difference in the median time to neutrophil engraftment or platelet engraftment between poor and good mobilizers, poor mobilizers received less dose of melphalan than good mobilizers (140-180 vs 200 mg/m 2 ). It is reported that reduced dose of melphalan is only one prognostic factor for shorter OS in patients with light-chain amyloidsis who receive autologous transplantation. 19 Thus, the long-term followup is needed to evaluate this effect.
In conclusion, mobilization in newly diagnosed patients with POEMS syndrome is still challenging with low yields of CD34 þ cells and high mobilization-related morbidity. Hepatomegaly is an independent prognostic factor for poor mobilization in patients with POEMS syndrome. Combination of CY and G-CSF is a preferred mobilization regimen. Appropriate pretreatment before mobilization might improve the efficiency of mobilization and reduce the mobilization-related morbidity in newly diagnosed patients with POEMS syndrome.
